AIMS v. US DEA

AIMS v. US DEAWe’re in Reuters:
https://www.reuters.com/legal/litigation/week-ahead-health-aug-30-2021-2021-08-27/

Thursday, Sept. 2

1 p.m. – The 9th U.S. Circuit Court of Appeals will hear a challenge to the Drug Enforcement Administration’s determination in February that it lacked authority to waive any provision of the Controlled Substances Act to allow medical use of psilocybin, the active chemical in magic mushrooms. The challenge was brought by a Seattle doctor, Sunil Aggarwal, and his clinic and research institute, the Advanced Integrative Medical Science Institute, seeking to give psilocybin to terminally ill patients to treat depression and anxiety under Washington’s “right to try” law, which aims to give certain patients access to experimental therapies.

The case is AIMS v. USDEA, 9th U.S. Circuit Court of Appeals, No. 21-70544. For plaintiffs: Matthew Zorn of Yetter Coleman. For the government: Thomas Pulham of the U.S. Department of Justice.
—-

Oral arguments in this case will occur this Thursday (9/2). View here. It is on the 1 pm schedule.
https://www.ca9.uscourts.gov/ (click on livestream)

Calendar Call at 1 pm. But it may not be the first case heard. Here’s the case data:

21-70544 AIMS v. USDEA – Petition for review of the U.S. Drug Enforcement Administration (DEA)’s final agency action, issued February 12. 2021, determining that the DEA had no authority to waive any of the Controlled Substances Act’s requirements, pursuant to the Right to Try, for medical use of psilocybin.
https://www.ca9.uscourts.gov/calendar/monthly_sittings/94554.html
It will also be archived and available to view for playback the following day.

Wish our team of lawyers luck and good fortune. This is a closely watched case.

Thanks,
Sunil Aggarwal, MD, PhD, FAAPMR
Co-Director, AIMS Institute

Latest Blog Posts

AIMS INSTITUTE’S COGNITIVE DECLINE PROTOCOL

AIMS INSTITUTE’S COGNITIVE DECLINE PROTOCOL

LJ STANDISH AND DAVID JAMES Dr. Standish and her team can help improve brain function, improve memory and slow cognitive decline in Alzheimer’s disease.  Please make an appointment to start.  Call 206-420-1321.  Scientific Rationale A protocol incorporating low-dose lithium orotate, Lion’s Mane mushroom extract, NADH, transcranial magnetic stimulation (TMS), and blood sugar regulation counseling is scientifically rational for treating cognitive decline based on mechanistic, preclinical, and emerging human studies. Low-Dose Lithium Orotate (5 mg/day) Recent brain tissue studies link low brain lithium to the onset and progression of Alzheimer’s disease, with deficiency accelerating synaptic loss and cognitive decline. Low-dose lithium orotate has ...

Read More
One Doctor’s Campaign to Let the Dying Take Psychedelics

One Doctor’s Campaign to Let the Dying Take Psychedelics

Psilocybin mushrooms on a dehydrator tray. Photographer: Jason Connolly/AFP/Getty Images By Charles Gorrivan September 3, 2025 at 3:00 AM PDT Corrected September 3, 2025 at 9:04 AM PDT Hi, it’s Charles in New York. When Brave New World author Aldous Huxley was on his deathbed in 1963, his wife injected him with two doses of LSD, the powerful psychedelic, as he slipped away. Was Huxley on to something? More on that in a moment, but first … Today’s must-reads RFK Jr. set new priorities for the CDC after firing its director. A big Danish pension fund bets that Novo Nordisk ...

Read More
Call Us Text Us
Skip to content